Bristol-Myers enlists DKSH to push its drugs in Asia

Bristol-Myers Squibb ($BMY) is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.

Under the agreement, DKSH will provide marketing, sales, warehousing, distribution and collection for Bristol-Myers in Hong Kong, Malaysia, Singapore, Taiwan, Thailand and Vietnam. For Bristol-Myers, the deal allows it to consolidate its number of service providers, reducing costs and oversight, while DKSH is using its latest contract as a springboard to more growth, the company said.

Last year, the Swiss firm's healthcare business brought in about $4.9 billion, and it has expanded to employ about 9,000 people across 150 sites in 14 countries, the company said.

The Bristol-Myers re-up is DKSH's fifth Big Pharma partnership over the past year, on the heels of Asia-focused deals with Sanofi ($SNY), Bayer, GlaxoSmithKline ($GSK) and Pfizer ($PFE).

DKSH has been expanding its offerings around the continent over the past year, getting into contract manufacturing and closing bolt-on acquisitions to grow its footprint. In February, DKSH bought out a Macau distributor to widen its regional presence, and, last summer, the company opened a 14,000-square-foot South Korean facility to distribute its clients devices, drugs and medical supplies in that country's swelling market.

- read the statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.